MEDI-493 humanized monoclonal that neutralizes respiratory syncytial virus: Began Phase I trial of safety, pharmacokinetics, and immunogenicity in healthy adult

MedImmune Inc. (MEDI), Gaithersburg,

Read the full 48 word article

How to gain access

Continue reading with a
two-week free trial.